International name: Harvoni (Sofosbuvir + Ledipasvir)
Name of generic: HEPCVIR-L
Manufacturer: Cipla Ltd.
Dosage: 400/90 mg
Type of packaging: can 28 tablets
HEPCVIR-L – a real bestseller against HCV from CIPLA (INDIA), an inhibitor of RNA polymerase, is approved for the treatment of patients infected with hepatitis C virus 1 and 4 genotype. HEPCVIR-L is the first FDA-approved therapy for the treatment of HCV, in which no collateral is assigned to the drug COPEGUS or short interferons. HEPCVIR-L is the official generic of Harvoni and produced in India under a patent of the copyright holder that proves its full pharmaceutical bioequivalence with the original Harvoni.
During long-term clinical studies have been proved not only by the high activity of Harvoni against the virus, but also its remarkably low toxicity. The study involved more than 1650 patients with viral hepatitis C 1 genotype. The course of treatment lasted only 84 days. At the end of therapy in 1600 patients have achieved their initial aim of treatment is the absence of the virus. Side effects that occurred because of reception of Harvoni (sofosbuvir + ledipasvir) were not clearly expressed and were accompanied mainly headache and fatigue.
FOR THE TREATMENT OF HEPATITIS C YOU CAN WHATSAPP/ VIBER US – +919555604444
Or email us at firstname.lastname@example.org
How to Buy Hepcvir L tablet from India, learn about the availability of drugs, Online price of Hepcvir L tablet in India and order delivery?
You can get answers to all your questions by submitting an inquiry on our product page.
Hepcvir-L is dispensed by prescription and should be used under proper medical guidance and control. All information presented here is given only for General educational purposes and is not medical or pharmaceutical advice. Advice on the application should be sought from qualified medical and pharmaceutical advisers.
The company “Cipla Ltd”, the global pharmaceutical company which uses cutting edge technology and innovation to meet the daily needs of all patients, announced the launch of a generic product, “Ledipasvir – Sofosbuvir” under the trade name Hepcvir-L in India. The drug Hepcvir-L is the first combined fixed dose for oral administration is once a day approved for treatment of patients with chronic hepatitis C genotype 1.
Implementation of the combined drug ” Ledipasvir – Sofosbuvir” a fixed dose for oral administration provides, therefore, a new treatment without interferon and ribavirin and powerful tool in the fight against hepatitis C genotype 1.
Commenting on the launch of the drug ” Ledipasvir – Sofosbuvir”, Mr. Subhani Saxena, MD and head of the International Department of the company “Cipla limited” (Cipla Limited) said: “the Company “Cipla” always tried to supply the market with best-in-class affordable medicines for patients, while the start of production of the drug ” Ledipasvir – Sofosbuvir” is the next step in the promotion of optimal treatment of patients suffering from the hepatitis C virus genotype 1″.
In the world, more than 185 million people are infected with hepatitis C. Approximately 12-18 million Indians are infected with the disease. It was noted that 3 out of 4 people affected with hepatitis C, are unaware of the infection because this disease has no specific symptoms.
With the aim of attracting attention of the population and of product supply to existing patients of the company “Cipla” has taken the initiative ACT-C (A=Awareness (awareness), C= Counselling (counselling), T = Treatment of Hepatitis –C (the treatment of hepatitis – C)), which is a patient support program. It helps in drawing attention to hepatitis C and the establishment of contact with patients affected by this disease. The company “Cipla” also launched a website providing a “single window” for information on hepatitis C.